A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Brief Summary: This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Detailed Description: All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.

Recruitment & Eligibility

Inclusion Criteria

Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
Must have received CRISPR CAR T cellular therapy.

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Non Interventional	Non Interventional	All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.

Primary Outcome Measures

Name	Time	Method
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.	15 years	The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.

Secondary Outcome Measures

Name	Time	Method
The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment	15 years	Overall survival will be calculated as the time between the initial dose of CRISPR CAR T cellular therapy in the parent study and death due to any cause. Duration of remission/response will be calculated as the time between the first objective response to first disease progression or death due to any cause.

Locations (21): Stanford
🇺🇸
Stanford, California, United States
UT Southwestern
🇺🇸
Dallas, Texas, United States
Peter MacCallum Cancer Center
🇦🇺
Melbourne, Victoria, Australia
Yale New Haven Hospital
🇺🇸
New Haven, Connecticut, United States
University of Minnesota
🇺🇸
Minneapolis, Minnesota, United States
Oregon Health and Science University
🇺🇸
Portland, Oregon, United States
University of Utah-Huntsman Cancer Institute
🇺🇸
Salt Lake City, Utah, United States
City of Hope
🇺🇸
Duarte, California, United States
Cedars Sinai
🇺🇸
Los Angeles, California, United States
Emory
🇺🇸
Atlanta, Georgia, United States
University of Kansas
🇺🇸
Westwood, Kansas, United States
Washington University Saint Louis
🇺🇸
Saint Louis, Missouri, United States
MSKCC
🇺🇸
New York, New York, United States
University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Methodist Hospital-Sarah Cannon
🇺🇸
San Antonio, Texas, United States
Royal Prince Alfred Hospital
🇦🇺
Camperdown, New South Wales, Australia
University Hospital Hamburg-Eppendorf
🇩🇪
Hamburg, Germany
Sir Charles Gairdner
🇦🇺
Nedlands, Australia
Princess Margaret
🇨🇦
Toronto, Ontario, Canada
Montefiore Medical Center
🇺🇸
Bronx, New York, United States